Advanced Age-Related Diminished Ovarian Reserve
Conditions
Interventions
T1 group:Performed on an outpatient basis between days 3 and 7 of the menstrual cycle (patients are instructed to abstain from intercourse during this period). Under conscious sedation, a 35cm 19G sin
T2 group:Performed on an outpatient basis between days 3 and 7 of the menstrual cycle (patients are instructed to abstain from intercourse during this period). Under conscious sedation, a 35cm 19G sin
C1 group:Conventional assisted reproductive techniques are employed without prior intraovarian injection
Sponsors
Qinzhou Maternity and Child Healthcare Hospital
Eligibility
Sex/Gender
Female
Age
35 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1. Participants must sign an informed consent form; 2. Age 35–45 years; 3. BMI 18.5–28.0 kg/m^2; 4. AMH level =10 IU/L, or transvaginal ultrasound showing a total bilateral ovarian antral follicle count (AFC) <=5; 5. Patients agree to enter an IVF-ET cycle within 3 months after PRP combined with PBMCs ovarian injection treatment.
Exclusion criteria
Exclusion criteria: 1. Ovarian failure caused by non-natural factors such as chromosomal karyotype abnormalities, history of oophorectomy/partial oophorectomy, pelvic radiotherapy/chemotherapy, or autoimmune oophoritis; 2. Indications for preimplantation genetic testing (PGT); 3. Presence of untreated hydrosalpinx, known moderate or severe endometriosis, history of recurrent miscarriage, endometrial lesions, uterine malformations, or other diseases that may affect IVF-ET success; 4. Poorly controlled endocrine or metabolic disorders, such as pituitary, adrenal, pancreatic, liver, or kidney diseases, uncontrolled thyroid diseases, diabetes (HbA1c >7.0%), severe obesity or emaciation; 5. Factors affecting the safety of PRP/PBMCs treatment, such as platelet function disorders, coagulation abnormalities, active infections, history of malignancy, severe active autoimmune diseases, or allergies to related preparations; 6. Receiving targeted treatments within 3–6 months prior to enrollment that may interfere with efficacy evaluation, such as hormone replacement cycles, antioxidant therapy, IVF cycles, or other ovarian regeneration treatments; 7. Severe male factor infertility without planned use of ICSI or donor sperm; 8. Other factors deemed by the investigator to make participation inappropriate, or contraindications to fertility treatment/pregnancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cumulative Live Birth Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| LH Elevation / Spontaneous Ovulation Rate;Number of Oocytes Retrieved;Number of Mature Oocytes;Number of Fertilized Oocytes;Number of Cleavage-Stage Embryos;Number of High-Quality Embryos;Blastocyst Formation Rate;Number of Cryopreserved Embryos/Blastocysts;Full Embryo Cryopreservation Rate;ß-hCG Positivity Rate;Clinical Pregnancy Rate;Ongoing Pregnancy Rate (Pregnancy =10 weeks); | — |
Countries
China
Contacts
Public ContactHongbo Wu
Qinzhou Maternity and Child Healthcare Hospital
Outcome results
None listed